MBX Biosciences, Inc. (MBX) stock
MBXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$53.42+0.32 (+0.60%)
Close on Nov 18, 2026Market cap $2.57BP/E –Yield –
MBX Biosciences free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
MBX Biosciences's free cash flow for the twelve months ending Sep 30, 2026 was -$99.33M. For fiscal 2025 it was -$81.88M.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$81.88M | – |
| FY2024 | Dec 31, 2024 | -$55.56M | – |
| FY2023 | Dec 31, 2023 | -$32.11M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$36.07M | – |
| Q2 FY2026 | Jun 30, 2026 | -$23.52M | – |
| Q1 FY2026 | Mar 31, 2026 | -$20.65M | – |
| Q4 FY2025 | Dec 31, 2025 | -$19.09M | – |
| Q3 FY2025 | Sep 30, 2025 | -$21.94M | – |
| Q2 FY2025 | Jun 30, 2025 | -$18.14M | – |
| Q1 FY2025 | Mar 31, 2025 | -$22.71M | – |
| Q4 FY2024 | Dec 31, 2024 | -$16.13M | – |
| Q3 FY2024 | Sep 30, 2024 | -$14.72M | – |
| Q2 FY2024 | Jun 30, 2024 | -$13.72M | – |
| Q1 FY2024 | Mar 31, 2024 | -$10.98M | – |
| Q4 FY2023 | Dec 31, 2023 | -$11.20M | – |
See a number that looks wrong?